The SLC4A7 variant rs4973768 is associated with breast cancer risk: evidence from a case–control study and a meta-analysis
- First Online:
- Cite this article as:
- Chen, W., Zhong, R., Ming, J. et al. Breast Cancer Res Treat (2012) 136: 847. doi:10.1007/s10549-012-2309-9
- 468 Downloads
Recent genome-wide association study has identified a genetic variant rs4973768, located in 3′-UTR of solute carrier family 4, sodium bicarbonate cotransporter, member 7 (SLC4A7), was associated with increased risk of breast cancer (BC). However, several following replication studies cannot yield consistent results. We thus conducted a hospital-based case–control study including 485 patients and 514 controls, combined a meta-analysis including 108,632 cases and 135,818 controls to explore the relationship between this variant and BC risk. Our case–control study showed that rs4973768 was significantly associated with increased BC risk with the odds ratio (OR) of 1.29 (95 % confidence interval [CI]: 1.04–1.60) under the allelic model. In addition, the meta-analysis also indicated that the variant slightly increased the risk of BC with the pooled OR of the per-allele effect being 1.08 (95 % CI: 1.04–1.11) although with significant heterogeneity between studies. Stratified analyses showed that ethnicity, sample size, and study design may explain part of the heterogeneity. Moreover, the bioinformatics analysis suggested that this variant may influence the transcriptional capacity of SLC4A7. In summary, our results showed that the SLC4A7 variant, rs4973768, is associated with risk of BC although the underlying biologic mechanism warrants further studies.
KeywordsBreast cancer rs4973768 Case–control study Meta-analysis
Genome-wide association studies